Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
University of Arizona Cancer Center, Tucson, AZ, USA. Alison.Stopeck@stonybrookmedicine.edu.
Alison T
AT
Stopeck
Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Karim
K
Fizazi
Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Jean-Jacques
JJ
Body
Cancer Research UK Experimental Cancer Medicine Centres, St James's University Hospital, Leeds, UK.|Weston Park Hospital, University of Sheffield, Sheffield, UK.
Janet E
JE
Brown
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Michael
M
Carducci
Center for Comprehensive Gynecology Clinic, Mannheim, Germany.
Ingo
I
Diel
National Cancer Center Hospital, Tokyo, Japan.
Yasuhiro
Y
Fujiwara
Instituto de Investigación Sanitaria General Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Miguel
M
Martín
Tom Baker Cancer Centre, Calgary, AB, Canada.
Alexander
A
Paterson
Cross Cancer Institute, Edmonton, AB, Canada.
Katia
K
Tonkin
Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Neal
N
Shore
Lancaster Urology, Lancaster, PA, USA.
Paul
P
Sieber
Urology Associates, Christchurch, New Zealand.
Frank
F
Kueppers
The Urology Center of Colorado, Denver, CO, USA.
Lawrence
L
Karsh
Sarah Cannon Research Institute, Nashville, TN, USA.
Denise
D
Yardley
Amgen Inc., Thousand Oaks, CA, USA.
Huei
H
Wang
Amgen Inc., Thousand Oaks, CA, USA.
Tapan
T
Maniar
Amgen Inc., Thousand Oaks, CA, USA.
Jorge
J
Arellano
Amgen Inc., Thousand Oaks, CA, USA.
Ada
A
Braun